Per una migliore esperienza, mantieni il tuo browser aggiornato. Controlla qui le ultime versioni.

May 2023

Axxam and Promega announce agreement to develop smart assays for drug discovery service

Axxam and Promega announced the formalization of an agreement that will offer world-class early-stage drug discovery services for different classes of targets and cellular pathways.

Global clients will have facilitated access to innovative customized luminescence-based, cell-free and cellbased assays suitable to run in miniaturized and fully automated High-Throughput Screening (HTS) format, in search of novel drug candidates.
This agreement combines the expertise of global biotechnology manufacturer Promega in the creation and production of a large spectrum of luminescence-based tools with the strong background and capabilities of Axxam in the generation of cell-free and cell-based assays and HTS. The strategy aims at offering services for target identification/validation as well for hit discovery based on innovative assays able to smartly monitor important cellular processes like protein degradation, protein-protein and protein-nucleotide interactions, protein secretion, RNA splicing and transcription modulation.

These drug discovery platforms and expertise can be accessed, under a single contractual and project management arrangement, by pharmaceutical and biotech companies, as well as academic translational organizations around the world.
Stefan Lohmer
CEO at Axxam

Axxam has enjoyed a very close collaboration with Promega over many years to develop smart and HTScompatible assays for very challenging and innovative targets, which are being continuously discovered by the scientific community and explored in the life science industry. For us Promega is the ideal partner to leverage the outstanding scientific expertise in both companies to support and enable the life science industry in their drug discovery efforts.

Tom Livelli
Promega Vice President, Life Sciences Products & Services.

This agreement enables researchers working in new frontiers of drug discovery to access a broad range of robust and reliable assays to enhance their work. We are excited to team up with Axxam in this endeavor to offer innovative technologies focused on addressing key challenges in early-phase drug discovery.